SIGA Technologies Amends Proxy to Clarify Equity Plan Terms, Removes Director Compensation Cap
summarizeSummary
SIGA Technologies filed a supplement to its definitive proxy statement, clarifying terms for its proposed 6.5 million share increase to the 2010 Stock Incentive Plan, including removing a non-employee director compensation cap and specifying employee share limits.
check_boxKey Events
-
Proxy Statement Supplement Filed
SIGA Technologies filed a supplement to its definitive proxy statement, originally filed on April 28, 2026, for the upcoming Annual Meeting of Stockholders on June 9, 2026.
-
Equity Plan Amendment Clarified
The supplement amends and restates Proposal 4, which seeks stockholder approval to increase the shares available under the 2010 Stock Incentive Plan by 6,500,000 shares.
-
Director Compensation Cap Removed
An erroneously included cap on the value of equity awards and cash compensation for non-employee directors has been removed from the plan summary.
-
Employee Share Limit Specified
The 1,000,000-share limit for individual awards under the plan is clarified to apply only to Company employees.
auto_awesomeAnalysis
This DEFA14A provides important clarifications to the previously filed definitive proxy statement regarding the proposed increase of 6.5 million shares to the 2010 Stock Incentive Plan. The removal of the non-employee director compensation cap and the clarification that the 1,000,000-share limit applies only to employees are material details for shareholders to consider ahead of the June 9, 2026, Annual Meeting. If approved, the plan would increase the total shares available for issuance to 15,000,000, representing a potential dilution of 12.07% on a fully diluted basis, which is substantial. This move is aimed at retaining and attracting key talent, but the potential dilution and changes to director compensation terms warrant close attention from investors.
At the time of this filing, SIGA was trading at $4.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $343.9M. The 52-week trading range was $4.29 to $9.62. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.